Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
Open accessThe DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index; 14 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Plasma chromogranin A (CgA) is related to tumor burden and recommended in the follow-up of patients diagnosed with neuroendocrine tumors (NETs). The use of CgA in the workup of a suspected NET is more questionable. OBJECTIVE: To assess the positive predictive value (PPV) of CgA plasma concentrations above the upper reference limit (URL) in patients with suspected NET. METHOD: Patients referred to the NET Centre, Rigshospitalet, Copenhagen from 2015 to 2019 with clinically suspected NET were included if a CgA measurement was performed prior to referral. The utility of CgA was assessed by comparing pre-referral CgA concentrations to the outcome of a thorough workup. In 47 selected cases with continuously unexplained elevated CgA concentrations, a processing-independent analysis (PIA) for CgA was performed. RESULTS: A total of 197 patients were included. NET was ultimately diagnosed in 25 patients. CgA plasma concentrations were above the URL (elevated) in 19/25 patients diagnosed with NET. In total, 167/197 had elevated CgA concentrations at referral. The positive predictive value (PPV) of elevated CgA concentration was 11% (19/167). Proton pump inhibitor (PPI) treatment was identified as the possible cause of CgA elevation in 55/148 patients with falsely elevated CgA. CgA concentration was normal in 28/47 patients when using PIA. CONCLUSION: Our data do not support using measurement of CgA for screening when NET is suspected since the PPV was rather low. PPI treatment is a common cause of increased CgA concentrations and should always be discontinued before CgA measurement. PIA of CgA could be a way of excluding NET when suspicion is based primarily on elevated CgA.
Overview
CoChat Summary
TL;DR
In 197 patients referred to a specialized NET centre with suspected neuroendocrine tumors, elevated pre-referral plasma chromogranin A (CgA) had a positive predictive value of only 11% for a subsequent NET diagnosis. The authors conclude CgA is unsuitable for screening in suspected NET, that proton pump inhibitor (PPI) treatment is a frequent cause of false elevation, and that processing-independent analysis (PIA) of CgA may help exclude NET when suspicion rests mainly on elevated CgA.
Key findings
- NET was ultimately diagnosed in 25/197 patients; CgA was elevated in 19/25 (sensitivity 76%) and normal in 6/25 (24%). Sensitivity was 50% for localized disease, 80% with local lymph node metastases, and 100% with distant metastases.
- Of 167 patients with elevated pre-referral CgA, only 19 had NET, giving a PPV of 11%; this rose to 15% (16/109) when PPI-treated patients were excluded, and to 67% when CgA was severely elevated (>8 × URL) and PPI-treated patients were excluded. PPV in PPI-treated patients was 5%.
- PPI treatment was identified as a possible cause of CgA elevation in 55/148 patients with falsely elevated CgA; after discontinuing PPI for at least one week, CgA normalized in 28/46 cases, with mean concentration falling from 445 pmol/L (IQR 197–456) to 128 pmol/L (90–152), p < 0.0001.
- CgA PIA was normal in 28/47 patients with continuously unexplained elevated CgA340-348; in five cases this was used to disprove NET suspicion without further examinations.
- Risk of NET rose with CgA concentration: OR 1.12 per 100 pmol/L increase (p < 0.005), and 1.18 when PPI-treated patients were excluded (p < 0.001); no significant association was seen in PPI-treated patients (OR 0.96, p = 0.74).
Methods
- Retrospective single-centre study at the ENETS Centre of Excellence, Rigshospitalet, Copenhagen; patients referred 1 January 2015–31 December 2019 with clinically suspected or histologically verified NET were included if plasma CgA had been measured before referral. Exclusions (n = 32) were CgA measured with another assay, CgA measured after histological NET verification, or incomplete workup, leaving 197 patients (median age 60 years, range 20–88; 67% female).
- Pre- and post-referral CgA was measured with an in-house CgA340-348 radioimmunoassay (URL 130 pmol/L; inter-assay CV 11%); PIA of CgA (URL 1100 pmol/L) was performed in 47 selected cases with unexplained persistently elevated CgA.
- PPV, sensitivity, and odds ratios (binary logistic regression per 100 pmol/L CgA) were calculated; PPI discontinuation comparisons used the Wilcoxon signed rank test (SPSS 26).
Limitations
- Stated by the paper: patients with normal CgA are presumably rarely referred, so the authors likely do not see most true-negative and possibly some false-negative measurements; this could overestimate diagnostic sensitivity and underestimate specificity, and negative predictive value/specificity were therefore not calculated.
- Stated by the paper: PPI was paused for at least one week, and a longer pause might have normalized CgA in more cases.
- Evident from the text: the study is retrospective and single-centre, restricted to G1/G2 NETs (G3 NET and NEC patients were referred elsewhere, as were pituitary, thyroid, parathyroid, and adrenal cases), and the PIA subgroup (n = 47) was selected rather than consecutive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 44 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, diagnostic sensitivity and specificity depend on the assay type, analytic specificity and sensitivity of the antiserum employed [14], as does the fact that the CgA protein is heavily processed to smaller fragments [14,18,19,20].”
§ Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors > 1. Introduction
What the sources say
- Partly supportedcites [14] Rehfeld, 2007, Processing-Independent Quantitation of Chromogranin A in Plasma from Patients with Neuroendocrine Tumors and Small-Cell Lung Carcinomas, Clin. Chem. sourceExperimental — accuracy not yet measured
The Discussion states that diagnostic sensitivity varies with assay specificity, and the evaluation of diagnostic accuracy reports different sensitivities for the four CgA assays (page numbers unavailable). Materials and Methods describes the epitopes recognized by the antisera. The copy does not establish that diagnostic specificity depends on assay type or on the antiserum’s analytic sensitivity. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [18] Rehfeld, 2020, True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours, Scand. J. Gastroenterol. source
- Not checked — no full text of the sourcecites [19] Rehfeld, 2003, The Posttranslational Phase of Gene Expression: New Possibilities in Molecular Diagnosis, Curr. Mol. Med. source
- Not checked — no full text of the sourcecites [20] Jensen, 1999, Library of Sequence-specific Radioimmunoassays for Human Chromogranin A, Clin. Chem. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, proton pump inhibitor (PPI) treatment is a common cause of CgA elevation [5,15].”
- Also stated in: § Abstract · plain
“PPI treatment is a common cause of increased CgA concentrations and should always be discontinued before CgA measurement.”
- Also stated in: § 4. Discussion · boosted
“PPI is a well-known cause of falsely elevated CgA [5,13,15,32]”
§ Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors > 1. Introduction
What the sources say
- Supportedcites [5] Marotta, 2018, Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: More flaws than fame, Endocr. Relat. Cancer source
The ‘Non-oncological causes of CgA elevation’ section states that PPIs are the main iatrogenic cause of CgA elevation and describes how acid suppression leads to CgA overproduction. This supports the claim that PPI treatment is a common cause of increased CgA concentrations. (LLM, conf=0.94)
- Supportedcites [15] Gut, 2016, Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls, Arch. Med. Sci. source
The ‘Gastric disorders’ section states that CgA levels rise during PPI treatment and describes how PPIs can produce substantial elevations. The false-positive results table also lists PPIs as a factor affecting CgA concentration. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [13] Ardill, 2010, Circulating Biomarkers in Neuroendocrine Tumors of the Enteropancreatic Tract: Application to Diagnosis, Monitoring Disease, and as Prognostic Indicators, Endocrinol. Metab. Clin. N. Am. source
- Could not verifycites [32] Waldum, H.L., Sørdal, Ø.F., and Mjønes, P.G. (2019). The Enterochromaffin-like [ECL] Cell—Central in Gastric Physiology and Pathology. Int. J. Mol. Sci., 20. sourceExperimental — accuracy not yet measured
Section 4.2 says PPIs cause secondary hypergastrinemia, but does not say they elevate CgA. A search for “chromogranin” found mentions of chromogranin A in Section 2 and the references, but no passage linking PPI treatment to increased CgA concentrations or describing it as a common cause. (LLM, conf=0.76)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In accordance with previous studies, we found that normal CgA does not exclude NET, since 6 of 25 diagnosed patients did not have elevated plasma CgA [5,16].”
§ Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors > 4. Discussion
What the sources say
- Supportedcites [5] Marotta, 2018, Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: More flaws than fame, Endocr. Relat. Cancer source
The Conclusions state that CgA is normal in about 70% of non-functional, localized neuroendocrine neoplasms. This directly supports the point that a normal CgA result does not exclude a neuroendocrine tumor; the cited paper does not supply the citing authors’ separate figure of 6 of 25 patients. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [16] Lyubimova, 2016, Chromogranin As a Biochemical Marker of Neuroendocrine Tumors, Bull. Exp. Biol. Med. source
plainn = 25- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Furthermore, it is likely that a longer pause of PPI would have resulted in the normalization of CgA in more cases since prolonged treatment with PPI causes enterochromaffin-like (ECL)-cell hyperplasia [33,34].”
§ Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors > 4. Discussion
What the sources say
- Not checked — no full text of the sourcecites [33] Bektas, 2012, Effects of Helicobacter pylori infection and long-term proton pump inhibitor use on enterochromaffin-like cells, Ann. Gastroenterol.
- Supportedcites [34] Lundell, 2015, Systematic review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology, Aliment. Pharmacol. Ther. source
The citation supports the sentence’s premise that prolonged PPI treatment causes ECL-cell hyperplasia: the Discussion reports an increased prevalence after treatment. The prediction that a longer PPI pause would normalize CgA in more cases is the citing authors’ inference, not a finding attributed to this source. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CgA PIA has demonstrated a high diagnostic accuracy (i.e., diagnostic sensitivity and specificity) compared to the CgA340-348 RIA and other CgA assays without trypsin cleavage prior to measurement [14,18].”
§ Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors > 4. Discussion
What the sources say
- Partly supportedcites [14] Rehfeld, 2007, Processing-Independent Quantitation of Chromogranin A in Plasma from Patients with Neuroendocrine Tumors and Small-Cell Lung Carcinomas, Clin. Chem. sourceExperimental — accuracy not yet measured
Table 4A (Discussion; page unavailable) reports high diagnostic sensitivity for CgA PIA (0.82), exceeding two sequence-specific assays but below the CgA(340–348) RIA (0.91). The Discussion says both PIA and that RIA are sensitive tools and that determining which is superior requires a larger study. The cited passages do not establish comparative diagnostic specificity, so they support only part of the claimed diagnostic accuracy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [18] Rehfeld, 2020, True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours, Scand. J. Gastroenterol. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
36 more claims · 1 with their cited sources checked
Create a free account to see all 58 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 10
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors > Abstract
“CgA concentration was normal in 28/47 patients when using PIA.”
§ Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors > 3. Results > 3.4. Causes of Elevated CgA Apart From NET
“In 28 patients, the CgA PIA was within normal range while simultaneously CgA340-348 was still elevated. In the remaining 19 cases, simultaneous plasma CgA340-348 and CgA PIA were both elevated (n = 17) or within normal range (n = 2).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Diagnostic imaging was performed less than 6 months prior to referral in 123 patients (60%)”
§ Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors > 3. Results > 3.1. Baseline Characteristics
Reported 60 · recomputed 62.436548
Citations
Cites
The 2019 WHO classification of tumours of the digestive system
Nagtegaal, I. D., Odze, R. D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., Washington, K. M., Carneiro, F., Cree, I. A., & the WHO Classification of Tumours Editorial Board (2020) · Histopathology · doi:10.1111/his.13975 · Cited by 4,192 · cited 2×
“G3 NET and NEC patients [2] were referred to the”
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586 · cited 1×
“Most small intestinal (SI)-NETs produce serotonin and other vasoactive molecules which may cause carcinoid syndrome in the presence of liver metastases [6,10,11].”
BackgroundENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum
Niederle, B., Pape, U.-F., Costa, F., Gross, D., Kelestimur, F., Knigge, U., Öberg, K., Pavel, M., Perren, A., Toumpanakis, C., et al. (2016) · Neuroendocrinology · doi:10.1159/000443170 · Cited by 474
Self-citationThe primary structure of human chromogranin A and pancreastatin.
Konecki, D. S., Benedum, U. M., Gerdes, H. H., & Huttner, W. B. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45486-5 · Cited by 288 · cited 1×
“It is a precursor protein of 439 amino acids [12].”
BackgroundLundell, L., Vieth, M., Gibson, F., Nagy, P., & Kahrilas, P. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13324 · Cited by 258 · cited 1×
“Furthermore, it is likely that a longer pause of PPI would have resulted in the normalization of CgA in more cases since prolonged treatment with PPI causes enterochromaffin-like (ECL)-cell hyperplasia [33,34].”
BackgroundJohnbeck, C. B., Knigge, U., Loft, A., Berthelsen, A. K., Mortensen, J., Oturai, P., Langer, S. W., Elema, D. R., & Kjaer, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.180430 · Cited by 243
Self-citationLANZON‐MILLER, S., POUNDER, R. E., HAMILTON, M. R., BALL, S., CHRONOS, N. A. F., RAYMOND, F., OLAUSSON, M., & CEDERBERG, C. (1987) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1987.tb00623.x · Cited by 188 · cited 1×
“In patients who cannot discontinue PPI, H2 receptor antagonist (H2RA) replacement may be tried during one or two weeks of PPI discontinuation [35] as H2RA affects gastric acidity, gastrin and CgA levels to a lesser extent than PPI [36].”
BackgroundInterest of Chromogranin A for diagnosis and follow-up of endocrine tumours
Nehar, D., Lombard‐Bohas, C., Olivieri, S., Claustrat, B., Chayvialle, J., Penes, M., Sassolas, G., & Borson‐Chazot, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02030.x · Cited by 177
Janson, E. T., Knigge, U., Dam, G., Federspiel, B., Grønbaek, H., Stålberg, P., Langer, S. W., Kjaer, A., Arola, J., Schalin-Jäntti, C., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1921262 · Cited by 167
Self-citationMarotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms
Leoncini, E., Boffetta, P., Shafir, M. K., Aleksovska, K., Boccia, S., & Rindi, G. (2017) · Endocrine · doi:10.1007/s12020-017-1273-x · Cited by 159 · cited 1×
“Neuroendocrine neoplasms (NENs) are rare heterogenous tumors which may arise in several different anatomical sites such as small intestine, pancreas and lungs [1].”
BackgroundChromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Gut, P., Czarnywojtek, A., Fischbach, J., Bączyk, M., Ziemnicka, K., Wrotkowska, E., Gryczyńska, M., & Ruchała, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.57577 · Cited by 144
Modlin, I. M., Kidd, M. S., Malczewska, A., Drozdov, I. A., Bodei, L., Matar, S., & Chung, K.-M. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.05.002 · Cited by 138
Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., et al. (2017) · Neuroendocrinology · doi:10.1159/000458155 · Cited by 136 · cited 1×
“In the ENETS (European Neuroendocrine Tumor Society) guidelines [21], measurement of CgA is recommended during follow-up of patients diagnosed with NET since plasma concentrations are related to tumor burden [14,18] and an increase in plasma concentration of CgA may be a predictor of disease progression [22,23].”
BackgroundSelf-citationGuilmette, J. M., & Nosé, V. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000201 · Cited by 118
Synaptophysin and neurofilament proteins as markers for neuroendocrine tumors.
Miettinen, M. (1987) · PubMed · Cited by 100
Complications from carcinoid syndrome: Review of the current evidence
Mota, J. M., Sousa, L. G., & Riechelmann, R. P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.662 · Cited by 99 · cited 2×
“SI-NETs rarely cause carcinoid syndrome before metastasizing to the liver, since the liver metabolizes bioactive molecules such as serotonin [10,11].”
BackgroundZhang, P., Yu, J., Li, J., et al. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/2340389 · Cited by 86 · cited 1×
“These imaging modalities are considered the most sensitive in diagnosing or excluding G1 and G2 NETs [29,41].”
BackgroundNikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E. (2008) · Pancreatology · doi:10.1159/000152000 · Cited by 84
Bardram, L., & Rehfeld, J. F. (1988) · Analytical Biochemistry · doi:10.1016/0003-2697(88)90580-5 · Cited by 75 · cited 1×
“To cope with such variability, processing-independent analysis has been developed [27] and also applied to CgA [14,18,19,27].”
MethodSelf-citationDelays and routes to diagnosis of neuroendocrine tumours
Basuroy, R., Bouvier, C., Ramage, J. K., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5057-3 · Cited by 66 · cited 1×
“A substantial delay in the diagnosis of NETs has been reported [7,40] highlighting the need for increased awareness of this rare type of tumor.”
BackgroundThe Posttranslational Phase of Gene Expression: New Possibilities in Molecular Diagnosis
Rehfeld, J., & Goetze, J. (2003) · Current Molecular Medicine · doi:10.2174/1566524033361717 · Cited by 59 · cited 3×
“Therefore, measurement of a single CgA fragment in the post-translational processing cascade may lead to varying results among different patients [19].”
MethodResultSelf-citationPancreatic neuroendocrine tumors: contemporary diagnosis and management
Parbhu, S. K., & Adler, D. G. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1210474 · Cited by 57 · cited 1×
“, able to produce and release bioactive peptides or amines to the bloodstream in contrast to non-functional NETs [4,5].”
BackgroundBiological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase
Braga, F., Ferraro, S., Mozzi, R., Dolci, A., & Panteghini, M. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.09.005 · Cited by 49 · cited 1×
“Two studies have been conducted regarding biological variation of CgA both supporting that within-subject variability could have caused marginally elevated CgA, which would later normalize spontaneously [37,38].”
BackgroundArdill, J. E. S., & O’Dorisio, T. M. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.09.001 · Cited by 49
RELATIONSHIP BETWEEN RENAL FUNCTION AND BLOOD LEVEL OF CHROMOGRANIN A
Tramonti, G., Ferdeghini, M., Annichiarico, C., Norpoth, M., Donadio, C., Bianchi, R., & Bianchi, C. (2001) · Renal Failure · doi:10.1081/jdi-100104728 · Cited by 48 · cited 1×
“73 m2 had significantly increased levels of CgA [28].”
Backgroundon behalf of, N. I. K. E., Fanciulli, G., Ruggeri, R. M., Grossrubatscher, E., Calzo, F. L., Wood, T. D., Faggiano, A., Isidori, A., & Colao, A. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09547-8 · Cited by 47 · cited 3×
“The most frequent symptoms in the carcinoid syndrome are flushing and diarrhea [11].”
BackgroundKorse, C. M., Muller, M., & Taal, B. G. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.380 · Cited by 47 · cited 1×
“In patients who cannot discontinue PPI, H2 receptor antagonist (H2RA) replacement may be tried during one or two weeks of PPI discontinuation [35] as H2RA affects gastric acidity, gastrin and CgA levels to a lesser extent than PPI [36].”
BackgroundThe Enterochromaffin-like [ECL] Cell—Central in Gastric Physiology and Pathology
Waldum, H. L., Sørdal, Ø. F., & Mjønes, P. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102444 · Cited by 45 · cited 2×
“cause of falsely elevated CgA [5,13,15,32], but even after excluding the substantial number of patients treated with PPI, the overall PPV of elevated CgA was only 15%.”
BackgroundBørglum, T., Rehfeld, J. F., Drivsholm, L. B., & Hilsted, L. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076158 · Cited by 42
Self-citationDam, G. A., Grønbæk, H., Sørbye, H., Thiis‐Evensen, E., Paulsson, B., Sundin, A., Jensen, C., Ebbesen, D., Knigge, U., & Janson, E. T. (2019) · Neuroendocrinology · doi:10.1159/000503833 · Cited by 40 · cited 1×
“In the ENETS (European Neuroendocrine Tumor Society) guidelines [21], measurement of CgA is recommended during follow-up of patients diagnosed with NET since plasma concentrations are related to tumor burden [14,18] and an increase in plasma concentration of CgA may be a predictor of disease progression [22,23].”
BackgroundSelf-citationPresenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours
Basuroy, R., Bouvier, C., Ramage, J. K., et al. (2018) · Neuroendocrinology · doi:10.1159/000488510 · Cited by 38 · cited 1×
“A substantial delay in the diagnosis of NETs has been reported [7,40] highlighting the need for increased awareness of this rare type of tumor.”
BackgroundLibrary of Sequence-specific Radioimmunoassays for Human Chromogranin A
Børglum Jensen, T., Hilsted, L., & Rehfeld, J. F. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.4.549 · Cited by 33
Self-citationPrognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine
Fuksiewicz, M., Kowalska, M. M., Kolasińska-Ćwikła, A., et al. (2018) · Endocrine Connections · doi:10.1530/ec-18-0059 · Cited by 27 · cited 1×
“In the ENETS (European Neuroendocrine Tumor Society) guidelines [21], measurement of CgA is recommended during follow-up of patients diagnosed with NET since plasma concentrations are related to tumor burden [14,18] and an increase in plasma concentration of CgA may be a predictor of disease progression [22,23].”
BackgroundJilesen, A. P. J., Busch, O. R. C., van Gulik, T. M., Gouma, D. J., & Nieveen van Dijkum, E. J. M. (2014) · Digestive Surgery · doi:10.1159/000370007 · Cited by 26 · cited 1×
“Important factors determining CgA concentrations are NET type, secretory activity and extent of disease [5,16,17].”
BackgroundGonzález‐Flores, E., Serrano, R., Sevilla, I., Viúdez, A., Barriuso, J., Benavent, M., Capdevila, J., Jimenez-Fonseca, P., López, C., & García‐Carbonero, R. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1980-7 · Cited by 25
Biological variation of plasma chromogranin A
Dittadi, R., Meo, S., & Gion, M. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.022 · Cited by 20 · cited 1×
“Two studies have been conducted regarding biological variation of CgA both supporting that within-subject variability could have caused marginally elevated CgA, which would later normalize spontaneously [37,38].”
BackgroundChromogranin As a Biochemical Marker of Neuroendocrine Tumors
Lyubimova, N. V., Churikova, T. K., & Kushlinskii, N. E. (2016) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-016-3254-0 · Cited by 20 · cited 2×
“Important factors determining CgA concentrations are NET type, secretory activity and extent of disease [5,16,17].”
BackgroundRehfeld, J. F., Broedbaek, K., Goetze, J. P., Knigge, U., & Hilsted, L. M. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1759141 · Cited by 13 · cited 9×
“None of the CgA fragments have better diagnostic accuracy than processing-independent analysis (PIA) of CgA [18].”
BackgroundMethodResultInfluentialSelf-citation(2012) · Europe PMC (PubMed Central) · Cited by 10
Janson, E. T., Sorbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., Ladekarl, M., Langer, S. W., Mortensen, J., Schalin-Jäntti, C., et al. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.941999
Self-citation
Cited by
Ciobanu, O., Martin, S. C., & Fica, S. V. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10914 · Cited by 19
Wang, Y., Huang, B., Fu, Q., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12107-w · Cited by 11
“Moreover, CgA also can be expressed in other cells, with low specificity and limited application.(27) In recent studies, it was concluded that the sensitivity and specificity of liquid biopsy were higher than those of CgA.”
BackgroundThiis‐Evensen, E., Kjellman, M., Knigge, U., Grønbæk, H., Schalin‐Jäntti, C., Welin, S., Sørbye, H., Schneider, M. D. P., Belusa, R., & The Nordic NET Biomarker Group (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13176 · Cited by 10
Self-citationRole of Chromogranin A in the Diagnosis and Follow-up of Neuroendocrine Tumors
Nguyen, M., Li, M., Travers, A., & Segelov, E. (2022) · Pancreas · doi:10.1097/mpa.0000000000002132 · Cited by 5
van Balveren, J. A., Erdem‐Eraslan, L., de Venne, W. P. H. G. V., Doggen, C. J. M., Hofland, J., Oosterhuis, W. P., de Rijke, Y. B., Hoedemakers, R. M. J., & Kusters, R. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.013 · Cited by 4
“The specificity of CgA assays as a diagnostic marker is limited in a population with other diseases, such as inflammatory bowel disease and renal failure [11,12].”
Background
Metadata
- Authors
- Baekdal, J., Krogh, J., Klose, M., Holmager, P., Langer, S. W., Oturai, P., Kjaer, A., Federspiel, B., Hilsted, L., Rehfeld, J. F., Knigge, U., & Andreassen, M.
- Affiliations
- ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
- Copenhagen University Hospital (DK)
- University of Copenhagen (DK)
- ORCID
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2020-10-29
- Volume
- 10
- Issue
- 11
- Pages
- 881
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC7693015
- OpenAlex
- W3096514914
- Cited by
- 17
- References
- 44
- Citations by year
- 2026: 3 · 2025: 6 · 2022: 7 · 2021: 1
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Keywords
- chromogranin A, neuroendocrine tumors, diagnostic accuracy, positive predictive value, proton pump inhibitors, cancer screening, plasma biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.